These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 39128063)
1. Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Feng G; Feng Y; Yao S; Huang X; Peng Z; Tang Y; Tang W; Li Z; Wang H; Liu H Turk J Gastroenterol; 2024 Apr; 35(4):266-279. PubMed ID: 39128063 [TBL] [Abstract][Full Text] [Related]
2. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175 [TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study. Huang Z; Chen T; Li W; He W; Liu S; Wu Z; Li B; Yuan Y; Qiu J Int Immunopharmacol; 2024 Sep; 139():112711. PubMed ID: 39029233 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618 [TBL] [Abstract][Full Text] [Related]
6. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Liu J; Zhang J; Wang Y; Shu G; Lou C; Du Z Medicine (Baltimore); 2022 Dec; 101(51):e32390. PubMed ID: 36595819 [TBL] [Abstract][Full Text] [Related]
7. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. Pang B; Zuo B; Huang L; You X; Liu T; Hao J; Yuan C; Yang C; Yee Lau W; Zhang Y Int Immunopharmacol; 2024 Aug; 137():112492. PubMed ID: 38906005 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. Wu Z; Gao J; Zhuang W; Yang J; Guo W J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099 [TBL] [Abstract][Full Text] [Related]
9. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study. Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Wang Z; Lin D; Luo T Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499 [TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma. Tsai WL; Sun WC; Chen WC; Chiang CL; Lin HS; Liang HL; Cheng JS Medicine (Baltimore); 2020 Aug; 99(32):e21489. PubMed ID: 32769883 [TBL] [Abstract][Full Text] [Related]
11. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH; Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578 [TBL] [Abstract][Full Text] [Related]
12. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352 [TBL] [Abstract][Full Text] [Related]
13. Quality of Life after Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Compared with Transcatheter Arterial Chemoembolization alone. Hassanin TM; Fouad Y; Hassnine A; Eisawy M; Farag N; Abdel Ghany W Asian Pac J Cancer Prev; 2021 Apr; 22(4):1255-1261. PubMed ID: 33906320 [TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164 [TBL] [Abstract][Full Text] [Related]
15. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma? Xie Y; Tian H; Xiang H Tumori; 2021 Aug; 107(4):292-303. PubMed ID: 32729385 [TBL] [Abstract][Full Text] [Related]
16. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744 [TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis. Li L; Tian J; Liu P; Wang X; Zhu Z Tumori; 2016 Jun; 2016(3):301-10. PubMed ID: 27002950 [TBL] [Abstract][Full Text] [Related]
18. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. Cai R; Song R; Pang P; Yan Y; Liao Y; Zhou C; Wang S; Zhou X; Wang H; Zhang H; Sun H; Ma H BMC Cancer; 2017 Nov; 17(1):714. PubMed ID: 29110700 [TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Lu L; Zeng J; Wen Z; Tang C; Xu N Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012244. PubMed ID: 30776082 [TBL] [Abstract][Full Text] [Related]